TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sosei Group ( (JP:4565) ) just unveiled an update.
Nxera Pharma announced it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals following the initiation of clinical development for ORX142, a novel orexin receptor 2 agonist. This development marks a significant step in the treatment of neurological and neurodegenerative disorders, with the revenue from these milestones recognized in the second and third quarters of 2025. The collaboration underscores Nxera’s strategic partnerships and its impact on advancing treatments in high-growth medical areas.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-powered biopharmaceutical company focused on developing and commercializing innovative specialty medicines to address unmet medical needs in Japan and globally. The company leverages its NxWave™ discovery platform to advance a pipeline of over 30 active programs targeting neurology, neuropsychiatry, metabolic diseases, and immunology and inflammation. Nxera operates in key locations across Japan, the UK, Switzerland, and South Korea and is listed on the Tokyo Stock Exchange.
Average Trading Volume: 927,477
Technical Sentiment Signal: Sell
Current Market Cap: Yen80B
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.